Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HBM HoldingsFRA:6XY +1.26%64 EV-to-EBIT is 13.37 as of Aug. 19, 2026, which is 1957% above its 10-year median of 0.65. GuruFocus rates FRA:6XY with a GF Score™ of 64/100 and a GF Value™ of €0.76 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 369 Biotechnology companies, HBM Holdings ranks better than 54.2% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
HBM Holdings's Enterprise Value for the quarter that ended in Dec. 2025 was €796.7 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. HBM Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €82.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HBM Holdings EV-to-EBIT Related Terms
HBM Holdings EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for HBM Holdings's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:6XY vs VRTX, REGN, RVMD: EV-to-EBIT Comparison
For the Biotechnology subindustry, HBM Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HBM Holdings EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HBM Holdings's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where HBM Holdings's EV-to-EBIT falls into.
HBM Holdings's current Enterprise Value is €1,104.4 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. HBM Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €82.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HBM Holdings (FRA:6XY) has a EV-to-EBIT of 13.37 as of Aug. 19, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on HBM Holdings and its competitors. This is 1957% above median its historical median of 0.65. According to the industry distribution chart, HBM Holdings ranks #169 out of 369 companies in the Biotechnology industry, placing it in the top 45.8%.
Is HBM Holdings' EV-to-EBIT too high?
HBM Holdings' current EV-to-EBIT of 13.37 is 1957% above median its 10-year median of 0.65. The Biotechnology industry median EV-to-EBIT is 15.95. HBM Holdings' value of 13.37 is 16.2% below this industry median. Based on the distribution chart, HBM Holdings ranks #169 out of 369 companies in the Biotechnology industry, which is above the industry midpoint. Overall, HBM Holdings has a GF Score™ of 64/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does HBM Holdings' EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, HBM Holdings ranks #169 out of 369 companies for EV-to-EBIT. This puts HBM Holdings in the upper half of its industry. The industry median EV-to-EBIT is 15.95. HBM Holdings' value of 13.37 is 16.2% below this benchmark. While the company's 10-year median is 0.65 vs. the industry median of 15.95, HBM Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.95, based on 369 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HBM Holdings's current EV-to-EBIT of 13.37 is 16.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on HBM Holdings and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HBM Holdings's current EV-to-EBIT is 13.37, which is 1957% above median its own 10-year median of 0.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HBM Holdings stock overvalued right now?
Based on GuruFocus' analysis, HBM Holdings (FRA:6XY) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.76, compared to a current price of €1.61 — trading 111.8% above its estimated fair value. The current EV-to-EBIT is 13.37, which is 1957% above median its 10-year median of 0.65 and 16.2% below the Biotechnology industry median of 15.95. HBM Holdings' overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For HBM Holdings (FRA:6XY), the current EV-to-EBIT is 13.37 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HBM Holdings (FRA:6XY) Overvalued in 2026?
Based on GuruFocus' analysis, HBM Holdings stock appears to be overvalued.
The current stock price of €1.61 is trading 111.8% above its estimated GF Value™ of €0.76.
GuruFocus considers HBM Holdings to be Significantly Overvalued.
Key valuation signals for FRA:6XY:
EV-to-EBIT: 13.37 (1957% above median its 10-year median of 0.65)
GF Value™: €0.76 vs. price of €1.61 (111.8% above fair value)
Industry Position: 16.2% below the Biotechnology median (#169 of 369)
No single metric tells the full story. See the FRA:6XY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. The majority of the revenue for the firm is generated from the Europe.
64GF Score
Get the complete analysis for FRA:6XY
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6XY has been successfully added to your 
